Vigil Neuroscience, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Vigil Neuroscience reports Q2 2025 results, highlighting progress on its acquisition by Sanofi for $8.00 cash plus a $2.00 CVR per share, while discontinuing its iluzanebart clinical program due to lack of efficacy.
Vigil Neuroscience reports a net loss of $22.4 million for Q1 2025 while advancing clinical trials for iluzanebart and VG-3927.
Vigil Neuroscience's third quarter 2024 report details ongoing clinical trials, financial status, and strategic developments in their neurodegenerative disease programs.
Vigil Neuroscience announced its Q2 2024 financial results, highlighting progress in clinical trials and a significant $40 million investment from Sanofi.
Vigil Neuroscience reports a net loss of $19.94 million for the first quarter of 2024, while advancing its clinical programs for neurodegenerative diseases.